Esperion has just lately obtained U.S. Meals and Drug Administration approval for label enlargement for its bempedoic acid and it consists of indications for main hyperlipidemia, alone or together with a statin, and is the one LDL-C reducing non-statin drug indicated for main prevention sufferers.
Blue Jet Healthcare Ltd. expects label enlargement to extend treatable inhabitants to 70 million affected person from 10 million presently. It expects acceleration from Q2 CY24. BlueJet has a multi-year contract to produce n2 intermediate for producing bempedoic acid; subsequently, the corporate may profit from acceleration in adoption of the treatment.
Now we have assumed income of Rs 2 billion from intermediate in FY26E whereas it has created capability with peak income of Rs 5 billion.
We keep our estimates and goal value of Rs 450 (26 occasions FY26E earnings per share). Keep Purchase.